Braly P S
Department of Reproductive Medicine, University of California, San Diego.
Oncology (Williston Park). 1992 Jan;6(1):23-8, 31; discussion 31-3.
In recent years, the use of flow cytometry has expanded from its initial research role to include the detection of clinically relevant abnormalities in the nuclear DNA content of tumor cells and variations in cell-growth kinetics. Retrospective studies have shown that DNA ploidy, and possibly the proliferative or S-phase fraction, is a valuable prognostic indicator in patients with gynecologic malignancies, including gestational trophoblastic disease, early- and late-stage ovarian cancer, squamous-cell cervical cancer and its precursor lesions, and endometrial adenocarcinoma. Further prospective studies are needed to establish the exact value of flow cytometry for gynecologic and other tumors. However, the prognostic value of this information certainly will influence the clinical management of patients with these malignancies in the near future.
近年来，流式细胞术的应用已从最初的研究角色扩展到包括检测肿瘤细胞核DNA含量的临床相关异常以及细胞生长动力学的变化。回顾性研究表明，DNA倍体以及可能的增殖或S期分数，是妇科恶性肿瘤患者的一个有价值的预后指标，这些妇科恶性肿瘤包括妊娠滋养细胞疾病、早期和晚期卵巢癌、宫颈鳞状细胞癌及其前驱病变以及子宫内膜腺癌。需要进一步的前瞻性研究来确定流式细胞术对妇科和其他肿瘤的确切价值。然而，这些信息的预后价值肯定会在不久的将来影响这些恶性肿瘤患者的临床管理。
